Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
The genotypic evolution of HBV quasi-species was analyzed in a nucleoside/nucleotide-naïve patient who developed resistance to entecavir. The lamivudine resistant quasi-species (rtM204V+/-rtL180M), absent at baseline, were emerged as early as 48 weeks after entecavir administration. Entecavir-resistant quasi-species (rtM204V+/-rtL180M plus S202G) were found after week 112 and gradually became the predominant mutations afterwards. The lamivudine- and entecavir-resistant mutations emerged closely in combination with the rtV207L, rtA222T, rtP237T or rtI163V substitutions. Our results indicated that the lamivudine-resistant mutations were developed first and may serve as a prequisite for subsequent entecavir-resistant mutations in this nucleoside/nucleotide-naïve patient.
Guo
Jin-Jun
JJ
Key Laboratory of Molecular Biology on Infectious Diseases, Ministry of Education, Institute for Viral Hepatitis, The Second Affiliated Hospital, Chongqing Medical University, 1 Yixueyuan Road, Chongqing 400016, China.
Li
Qing-Ling
QL
Shi
Xiao-Feng
XF
Zhang
Da-Zhi
DZ
Zeng
Ai-Zhong
AZ
Feng
Tao
T
Huang
Ai-Long
AL
D019943:Amino Acid Substitution / Q000235:genetics; D000998:Antiviral Agents / Q000494:pharmacology*; D004279:DNA, Viral / Q000235:genetics; D024882:Drug Resistance, Viral; D006147:Guanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006515:Hepatitis B virus / Q000145:classification / Q000187:drug effects* / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000821:virology*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology; D008297:Male; D020125:Mutation, Missense; D017422:Sequence Analysis, DNA
D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine; C413685:entecavir; D006147:Guanine